Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC and the American Academy of Ophthalmology. We will continue to see our patients and treat any urgent/emergent needs.

With all of our offices open, the following protocols are in place:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.

Research at the forefront of care

Retina Associates

Retina Associates has a team of researchers that are focused on advancing and improving the treatment of diseases of the retina, macula and vitreous through clinical studies, teaching, and development of new instruments and techniques. Our physicians have participated in a multitude of  research studies and in many our physicians have served as principal investigators or co-investigators.  Current studies that we are involved in are:

Enrolled Studies

1. DRCR:  Protocol T - A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema

2. Allergan:  BDP 1 A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, followed by masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)

3. MERCK:  EPOCH - A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease.  (We are conducting the ophthalmology portion of this study for KU Medical Center)

We have a few more upcoming studies with start-up dates in late spring.  More information will be published as it becomes available.

NOW ENROLLING

DRCR Protocol V:  This is a 2 year study for Treatment for Central Involved DME in Eyes with Very Good Visual Acuity (20/25 or better).  The treatment arms for this study are:
1)  Prompt focal laser + deferred Eylea
2)  Observation + deferred Eylea
3)  Prompt Eylea

OPHTHOTECH OPH1003:  This is a 2 year study to establish the safety and efficacy of intravitreous administration of Fovista (Anti PDGF-G Pegylated Aptamer) administered in combination wit Lucentis compared to Lucentis Monotherapy for subjects with Subfoveal NVAMD.

ORION Study:  This is an IST thru Dr. Victor Gonzales at Valley Retina in McAllen, TX.  It is a 1 year study comparing Ozurdex vs. Lucentis vs. Combination for Central Retinal Vein Occlusion.

Pan Optica PAN-01-101:  A Phase 1, 9-week trial to evaluate the Safety and Tolerability of Topical Ocular PAN-90806 (small molecule inhibitor of type 2 VEGF receptor) in patients with NVAMD.  Rescue treatment with Lucentis can be administered starting at Week 2.  Treatment arms include:
1)  1mg PAN-90806 BID x 8 weeks
2)  2mg PAN-90806 BID x 8 weeks
3)  4mg PAN-90806 QD x 8 weeks
 

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Retina Associates, PA

Retina Associates, PA is an advanced medical practice devoted to the diagnosis and treatment of retinal, macular, and vitreous diseases. Together, our eye care physicians belong to various prestigious organizations: 

  • American Board of Ophthalmology
  • American Medical Association
  • American Academy of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American College of Surgeons
  • American Society of Retina Specialists

Our mission is to help every patient preserve or restore their sight through our advanced treatment options. To discuss your needs with one of our doctors, request an appointment online or call us at (913) 831-7400.

Contact Us

Rate, Review & Explore

Social Accounts Sprite

Shawnee Mission Office

9301 W 74th St
Ste 210
Shawnee Mission, KS 66204

Open Today 8:00am - 5:00pm

What is the best time for you?

Add additional time

Tell us a bit about yourself...

(913) 831-7400 Send a message